Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086645 · ClinicalTrials.gov registry record · Phase 2
Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)
A Phase 2 study of Autistic Disorder, sponsored by Boston University.
- Completed
- Registry status
- Phase 2
- Development phase
- 149
- Enrollment target
- 6
- Study locations
NCT00086645: Completed Phase 2 study of Autistic Disorder, sponsored by Boston University.
NCT00086645 is a Phase 2 study of Autistic Disorder that has completed, run by Boston University. The registered enrollment target is 149 participants, above the 108-participant average among 27 other Autistic Disorder trials with a reported enrollment target (38% higher). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00086645, a Phase 2 study of Autistic Disorder, has completed, sponsored by Boston University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 149 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study will determine the efficacy and safety of citalopram compared to placebo in the treatment of children with autism.
Conditions Studied
Interventions
- OTHER placebo
- DRUG citalopram hydrobromide
Study Locations (6)
New York
- North Shore - Long Island Jewish Hospital - Great Neck
- Mount Sinai School of Medicine - New York
California
- UCLA Neuropsychiatric Institute - Los Angeles
Connecticut
- Yale University - New Haven
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
North Carolina
- University of North Carolina Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2004-04 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
What the finished NCT00086645 record still lists
NCT00086645 is an interventional study that assigns participants to a tested intervention. The registered 149 participants enrollment target is mid-sized for trials with a published cap, above the 108-participant average among 27 other Autistic Disorder trials with a reported enrollment target (38% higher).
The record links to 1 condition, with Autistic Disorder appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00086645 lists 6 locations in 5 states (New York, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT00086645 about?
NCT00086645 is a clinical study titled "Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)". This study will determine the efficacy and safety of citalopram compared to placebo in the treatment of children with autism.
What is the current status of trial NCT00086645?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 149 participants. The study started on 2004-04. Estimated completion is 2007-04.
What conditions does trial NCT00086645 study?
This clinical trial studies the following conditions: Autistic Disorder.
What interventions are being tested in trial NCT00086645?
The interventions under investigation include: placebo (OTHER), citalopram hydrobromide (DRUG).
Who is sponsoring clinical trial NCT00086645?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00086645 being conducted?
This trial has 6 study locations across California, Connecticut, New Hampshire, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autistic Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00086645's enrollment target sits among peer trials
149 8th of 27 higher than 20 of 27 other Autistic Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autistic Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism
ACTIVE NOT RECRUITING · Phase 2
-
Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism
COMPLETED · Phase 2
-
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
COMPLETED · Phase 2
-
A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders
COMPLETED · Phase 2
-
Donepezil HCl & Cognitive Deficits in Autism
COMPLETED · Phase 2
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04188535 · 149 participants · NA
Serial MRI Scans During Radiation Therapy
- NCT05828511 · 149 participants · Phase 1
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia